Character Group PLC
30 June 2004
Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Wednesday, 30 June 2004
IMMEDIATE RELEASE
The issuer advises the following replaces the holding in company announcement
released on 28 June 2004 under RNS number 2165A. Please be advised that the
total interest of ordinary shares should have been '5,045,000 ordinary shares of
5p each representing approximately 9.57% of the issued ordinary share capital'
and not '5,000,000 ordinary shares of 5p each and 9.5% of the issued ordinary
share capital' as previously stated.
All other details remain unchanged. The full amended text appears below:
The Character Group plc ('Company' or 'The Character Group')
Mittel Generale Investmenti S.p.A. ('Mittel') takes a stake of 9.57% in the
Company
The Company received notifications that on 25 June Mittel has purchased from
Valtidone S.p.A., 5,000,000 ordinary shares of 5p each of the Company ('Ordinary
Shares') in an 'off market' transaction.
Following these transactions, Valtidone S.p.A. has a notifiable interest of
2,030,000 Ordinary Shares, representing 3.85% of the issued share capital of the
Company, and Mittel has a notifiable interest of 5,045,000 Ordinary Shares,
representing approximately 9.57% of the issued ordinary share capital of the
Company.
Valtidone has informed the Directors that it has now completed its share
disposal programme, and intends to keep its current interest for the foreseeable
future as a long term investment.
Mittel, which was founded in 1885 and listed in the same year, is the oldest
investment bank listed on the Italian Stock Exchange. It specialises in
strategic investments and investment banking in both the public and private
markets.
Dr Guido de Vivo, CEO of Mittel, stated: 'The investment in The Character Group
is consistent with Mittel's policy of investing in companies that are well
managed, the management have a significant shareholding, and where the shares
are perceived to be undervalued'
Richard King, Chairman of The Character Group commented:
'We are delighted to have Mittel as our first really significant investor from
the financial markets. I believe that Mittel's broad range of expertise and
their desire to be proactive in helping the Company to take advantage of any
opportunities to grow either organically or through acquisition, will enable the
management to assess new opportunities with a more confident approach.'
Enquiries:
Richard King, Chairman Fiona Tooley
Kiran Shah, Group Finance Director Citigate Dewe Rogerson
The Character Group plc Tel: 0121 455 8370
Tel: 020 8949 5898 Mobile: 07785 703523
Mobile: 07836 250150 (RK)
Mobile: 07956 278522 (KS)
www.charactergroup.plc.uk
Dr Guido de Vivo
Mittel S.p.A.
Tel: +39 02 721411
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.